PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial
- 28 February 2020
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 223, 98-105
- https://doi.org/10.1016/j.ahj.2019.12.024
Abstract
No abstract availableFunding Information
- Amgen
- Amgen
This publication has 24 references indexed in Scilit:
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure PatientsJournal of the American College of Cardiology, 2013
- Validated, Electronic Health Record Deployable Prediction Models for Assessing Patient Risk of 30-Day Rehospitalization and Mortality in Older Heart Failure PatientsJACC: Heart Failure, 2013
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJournal of the American College of Cardiology, 2013
- Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudyEuropean Heart Journal, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT)European Journal of Heart Failure, 2009
- Dosing of Beta-Blocker Therapy Before, During, and After Hospitalization for Heart Failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure)The American Journal of Cardiology, 2008
- Predictors of mortality and morbidity in patients with chronic heart failureEuropean Heart Journal, 2005
- Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failureJournal of the American College of Cardiology, 2004